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Abstract 
Cerebral deposition of B-amyloid peptide @A) is a hallmark of Alzheimer’s disease. Concentration of /IA could play a critical role in the rate of 
amyloid deposition. It is therefore of considerable importance to identify proteases involved in processing ofpA. ‘251-labeled synthetic /IA specifically 
cross-linked to a single protein with M, = 110,000 in cytosol fractions from rat brain and liver. This protein was identified as insulin degrading enzyme 
(IDE) since the labeling of the 110 kDa protein was completely blocked by an excess of insulin, and anti-IDE monoclonal antibodies precipitated 
the labeled protein. Purified rat IDE effectively degraded /IA. 
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1. Introdwtion 
Alzheimer’s disease amyloid is composed of a 39-43 
residue /I-amyloid protein (BA) [l-3] that is derived from 
a set of larger transmembrane precursor proteins 
@4PPs) [4,5]. G rowing evidence is accumulating that 
processing of jL4PP may occur intracellularly [6-81 and 
that /IA is a normal product of cell metabolism [9-l 11. 
A recent finding that cultured human neurons generate 
/IA intracellularly before it is released into the medium 
[12] suggests the possibility that PA accumulation in Alz- 
heimer’s brain could result from defects in intracellular 
proteolytic machinery responsible for its breakdown. 
Thus, protease involved in processing ofBA is a poten- 
tial target for pharmacological treatment of the disease. 
We considered that among intracellular proteases 
which could participate in degradation of PA, the insulin 
degrading enzyme (IDE; EC 3.4.22.11) is a very likely 
candidate. IDE is a highly selective protease involved in 
the breakdown of certain peptide hormones [ 13-151. IDE 
does not have a strict specificity for any amino acid 
residue [16]. It has been suggested, however, that its 
specificity is based on recognition of specific secondary 
structures rather than specific peptide bonds [16]. It is 
interesting to note that although the IDE substrates, 
insulin, atria1 natriuretic peptide and glucagon, are 
greatly different in primary structure, they probably 
share a common structural motif allowing them to form 
amyloid fibrils under certain conditions in vitro [ 171 and 
in vivo [18,19]. In amyloid fibrils, different proteins have 
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been shown to be organized in a cross-j? conformation 
[ 171. Therefore, IDE specificity could be based on recog- 
nition of/3-structures either present on the surface of the 
substrate molecules or adopted upon binding to the pro- 
tease. This possibility suggests that IDE might also de- 
grade PA. 
Here we show that PA is a substrate for rat liver IDE. 
Furthermore, we demonstrate that IDE is the only pro- 
tein that can be specifically cross-linked to PA in crude 
extracts of rat brain and liver, suggesting for a role for 
IDE in the cellular processing of /3A. 
2. Materials and methods 
2.1. Materials 
The following materials were obtained: [‘2SI]insulin (1.2 kCiimmo1) 
from Dainabott (Tokyo, Japan), /JA,,, and PAi, from Bachem Cali- 
fornia (USA). Monoclonal antibodies to IDE (9Bl2) were kindly pro- 
vided by Dr. R. Roth (Stanford University, USA) or purified from 
ascites fluid provided by Dr. K. Shii (Kobe University, Japan) on 
protein G-Agarose. /3A,, was radiolabeled by the chloramine-T 
method using Na’*‘I (Amersham, England) and separated from unla- 
beled peptide and free iodine by reverse-phase HPLC. Bovine serum 
albumin was added immediately to the eluted fractions. Then, tri- 
fluoroacetic acid (TFA) and acetonitrile were removed under a gentle 
stream of N,. 
2.2. Degradation of DA,, and fiAl_zB by IDE 
IDE was purified from the cytosol fraction of rat liver in four chro- 
matographic steps (i.e. DEAE-Toyopearl, hydroxylapatite, pentyl- 
Agarose, TSK 3000 SW HPLC). The preparations of IDE were homo- 
geneous as analyzed by SDS-PAGE (Kurochkin and Goto, submitted). 
Freshly dissolved peptide solutions were used. Prior to degradation 
assay, synthetic peptides were centrifuged at 15,000 x g for 10 min. No 
evidence of precipitates was observed. The enzyme (0.2 ,ug) was incu- 
bated either with 1.2 nmol(5 pg) of synthetic PA,, or 3.4 mnol(l1 ,ug) 
of /JA,,, in 70 ~1 of 50 mM Tris-HCl buffer (PH 7.0) at 37°C. At 
various times, degradation was stopped by the addition of 0.7 ml of 
0.06% TFA, and the entire sample was injected into the RF318 reverse- 
phase HPLC column (particle size 5 pm, column dimensions 250 x 4.6 
mm) (Bio-Rad). The loaded column was eluted with a O-8096 linear 
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gradient of acetonitrile in 30 ml of 0.06% TFA at a flow rate of 0.5 
ml.min-‘. Elution was monitored by the absorbance at 220 
mu. 
2.3. Cross-linking conditions 
[‘Z51]Insulin (0.2 pmol) together with 50 ,ug of cytosol fraction (pre- 
pared by centrifugation of tissue homogenates at 100,000 x g for 60 
min) was incubated at 0°C in the absence or presence of 10m5 M of 
unlabeled peptides in a total volume of 50 pl PBS (20 mM sodium 
phosphate, pH 7.4, and 150 mM NaCl). After 30 min, 3 ~1 of disuccin- 
imidyl suberate (8.8 mM in 25% diiethylsulfoxide) was added 1231. The 
reaction was continued for 30 min at 0°C and was stopped by addition 
of 14 ~1 of denaturing buffer containina 5% SDS and 25% 2-mercao- 
toethanol. Different jrom [‘251]insulin cross-linking, ]“‘ESA,_,, (d.2 
pmol) was pre-incubated with 50 fig of cytosol fractions (56 pl)for 10 
min at 24°C following incubation with cross-linker for 15 rnin at the 
same temperature. 1; addition, the mixture additionally contained 
2 mM l,lO-phenanthroline and 5 mM EDTA to inhibit IDE activity. 
Samples were then heated at 1OO’C for 3 min and analyzed by SDS- 
PAGE on 8% separation gel [20]. The gel was stained, destained, dried 
and exposed to Image Plate (BAS 2000; Fuji, Japan). When [‘z51]/&2s 
was cross-linked with purified IDE the concentration of disuccinimidyl 
suberate in the cross-linking mixture was 1 mM. 
2.4. Immunoprecipitation of cross-linked protein 
[‘*‘II/%28 was cross-linked to a cytosolic fraction from rat brain. 
The reaction was stopped by the addition of 1~1 of 1 M Tris-HCl (pH 
7.4) per 50 ~1 of the mixture. Then aliquots (25 ~1) of the mixture were 
incubated with various concentrations of either anti-IDE monoclonal 
antibody 9B12 or normal mouse IgG overnight at 4°C in 100~1 of PBS 
containing 0.2% BSA, 1 mM PMSF and 0.01% NaN,. The immune 
complex was then precipitated with 30 ~1 of protein G-PLUS-Agarose 
(Oncogene Science Inc.). The supematants and washed immunoprecip- 
itates were analyzed by electrophoresis and autoradiography. 
2.5. Oxidative mod@ation of lysozyme 
Oxidative modification was carried out by a metal-catalized oxida- 
tion system with hen egg white lysozyme at a concentration of 5 mg/ml 
in a buffer containing 25 mM ascorbate, 0.1 mM FeCl,, 1 mM EDTA, 
100 mM NaCl and 50 mM potassium phosphate, pH 7.5. Incubation 
was performed at 37°C with shaking for 4 h. At the end of the incuba- 
tion period the sample was gel-filtrated on a Sephadex G-25 column 
equilibrated with 50 mM Tris-HCl, pH 8.5, at room temperature. The 
protein fraction separated from the FeCl,/ascorbate system was used 
for experiments. 
3. Results and discussion 
In our experiments, we used a synthetic full-length PA 
@A,,) and a shorter peptide corresponding to residues 
1-28 of PA GgA,,,). PA,, is known to have a high 
B-sheet content at physiological pH [21]. Monomeric 
PA,,, in solution is a mixture of a-helices and random 
coils [21] but it readily assumes ap-pleated conformation 
at high concentrations, forming amyloid fibrils morpho- 
logically resembling those seen in Alzheimer’s neurite 
plaques [22]. 
Endogenous IDE in cytosols from different tissues 
could be specifically cross-linked to [1251]insulin [23]. Ad- 
dition of @_28 to the cross-linking mixture prevented 
the labeling of IDE (Fig. la, lane 3), indicating that 
/?A,_** interacts with the enzyme. When purified rat IDE 
was incubated with synthetic pAi and BA1_28, the pep- 
tides were effectively hydrolyzed (Fig. 2a,b). The genera- 
tion of at least eleven proteolytic fragments from BA1_** 
(Fig. 2b) supports the view [16] that IDE is non-specific 
in hydrolyzing particular peptide bonds. These experi- 
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Fig. 1. (a) Cross-linking of [‘251]insulin to rat liver cytosol in the absence (lane 1) or presence of unlabeled insulin (lane 2) or PA,,, (lane 3). 
(b) Cross-linking of [‘251]/JA,_28 to rat brain or liver cytosols in the absence (lanes 1, 5) or presence of unlabeled /IA,,, (lane 2) /IA,, (lane 3) or 
insulin (lane 4). The radioactivity in the 66,000 molecular weight range corresponds to bovine serum albumin present in the [‘r51]insulin and [‘251]~A1_2s 
preparations. The radioactive band observed at the dye front is due to the non-cross-linked ‘ZSI-labeled peptides. The numbers on the left indicate 
M, x lo-‘. 
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Fig. 2. HPLC profiles of PA,, (a) and PA,,, (b) after incubation with IDE for indicated periods of time. 
ments, however, do not exclude the possibility that other 
cytosolic proteases participate in the breakdown of PA. 
Therefore, we performed covalent cross-linking of radio- 
iodinated /IA in the presence of tissue extracts. In the 
presence of either brain or liver cytosol fractions 
[1251#?A1_2S was specifically cross-linked only to one pro- 
tein of 110,000 kDa (Fig. lb, lanes 1,5). This specificity 
was confirmed by the fact that the 110 kDa labeled band 
was abolished by the addition of excess of unlabeled 
peptide (Fig. lb, lane 2). In addition, cross-linking of 
[1251J?A,_28 to the 110 kDa protein was inhibited by the 
addition of unlabeled full-length~amyloid peptide, /IA,, 
(Fig. lb, lane 3) or insulin (Fig. lb, lane 4) to the mixture. 
When the cross-linking mixture did not contain metal 
chelators known to inhibit the hydrolyzing but not the 
substrate-binding activity of IDE [24], no ‘2’I-labeled 110 
kDa band was observed (data not shown). This fact, in 
addition to proof of the highly specific interaction of PA 
with IDE, demonstrates the high susceptibility of the 
peptide to IDE action, that the interaction ofpA with the 
protease results in such rapid hydrolysis that the cross- 
linking reaction has no time to occur. Although the mo- 
lecular weight of the cross-linked band coincided with 
that of IDE, convincing evidence of its identity as IDE 
was obtained by immunoprecipitation experiments. 
Anti-IDE monoclonal antibody 9B12 [13] precipitated 
the [1251]jSA,_28.1 10 kDa protein complex from brain cy- 
tosol fractions (Fig. 3). No bands were seen precipitating 
with normal mouse IgG (data not shown). 
The finding that /IA is a highly specific substrate for 
IDE raises the possibility that factors which may affect 
the activity of this protease could cause an increase in the 
overall amount of PA and as a result lead to the forma- 
tion of insoluble amyloid deposits. Among these factors 
are other substrates which could compete for binding to 
the enzyme. Recent studies suggest that IDE is likely to 
be involved in the removal of oxidatively damaged pro- 
teins ([25]; Kurochkin and Goto, submitted) the progres- 
sive accumulation of which in aged brain is well docu- 
mented [26]. Oxidized but not native lysozyme inhibited 
cross-linking of [‘251]BA,_28 to purified IDE (Fig. 4), sug- 
gesting that abnormal proteins accumulating in aged 
36 
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Fig. 3. Immunoprecipitation of the cross-linked 110 kDa protein with anti-IDE monoclonal antibody 9Bl2. The numbers on the top indicate the 
concentration of the antibody. 
brain may inhibit the degradation of/3A. Alternatively, 
over-production ofj3A from the precursor protein would 
cause accumulation of abnormal proteins and as a result 
lead to the degeneration of nerve cells. 
We must also take into account a possible effect of pH 
on IDE activity. Decreased pH values (pH 6.6) are found 
in the brain from patients who have died from Alz- 
heimer’s disease [27]. We have demonstrated that bind- 
ing of PA to IDE is highly sensitive to a reduction in pH. 
The binding activity was reduced by 89% at pH 6.4 and 
by 63% at pH 6.6 compared with that at pH 7.4 (data not 
shown). Thus, slight acidification of the cytoplasm may 
alone significantly promote accumulation of /?A by inhi- 
bition of its binding to IDE. 
The fact that a naturally occurring 16 kDa fragment 
containing the /3A and the C-terminus of /3APP adopts 
the tertiary structure of /IA and has amyloidogenic prop- 
erties [28] raises the possibility that IDE could be in- 
volved in its degradation and of other immediate precur- 
sors for /?A. It remains unclear where /3APP processing 
occurs in neurons. Both the endosomal-lysosomal [6,7] 
and secretory [8] pathways are suggested to be involved 
in the generation of PA. Although IDE is primarily a 
cytosolic enzyme, it may be incorporated into the en- 
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Fig. 4. Effect of native and oxidatively modified lysozyme on cross- 
linking of (“‘I]/?A1_28 to IDE. Purified IDE (10 ng) was cross-linked 
with [‘251]/9A,_28 in the absence or presence of indicated amounts of 
either native or oxidatively mod&xl lysozyme and then analyzed by 
SDS-PAGE and autoradiography. 
dosome during vesicle formation and degrade internal- 
ized receptor-bound insulin before endosome acidifica- 
tion [29]. Identification of the subcellular compartment 
where IDE may come into contact with /?A remains to 
be determined. 
Our results suggest an important role for IDE in the 
genesis of Alzheimer’s disease and raise the interesting 
possibility of using this highly specific protease as a ther- 
apeutic agent to slow the progress of the disease by re- 
ducing /IA concentration. 
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